Rapid Micro Biosystems (NASDAQ:RPID) Major Shareholder Sells $190,120.00 in Stock

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) major shareholder Longitude Capital Partners Ii, sold 49,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $3.88, for a total transaction of $190,120.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Longitude Capital Partners Ii, also recently made the following trade(s):

• On Monday, February 2nd, Longitude Capital Partners Ii, sold 27,500 shares of Rapid Micro Biosystems stock. The stock was sold at an average price of $4.25, for a total value of $116,875.00.
• On Friday, January 30th, Longitude Capital Partners Ii, sold 46,000 shares of Rapid Micro Biosystems stock. The shares were sold at an average price of $4.54, for a total value of $208,840.00.
• On Friday, January 23rd, Longitude Capital Partners Ii, sold 7,739 shares of Rapid Micro Biosystems stock. The stock was sold at an average price of $4.06, for a total value of $31,420.34.

Rapid Micro Biosystems Stock Up 5.2%

Shares of NASDAQ RPID traded up $0.19 during mid-day trading on Friday, reaching $3.87. 132,257 shares of the company were exchanged, compared to its average volume of 359,926. Rapid Micro Biosystems, Inc. has a 1 year low of $1.86 and a 1 year high of $4.94. The firm has a 50-day moving average of $3.67 and a 200 day moving average of $3.40. The stock has a market cap of $171.52 million, a price-to-earnings ratio of -3.83 and a beta of 1.38. The company has a quick ratio of 2.95, a current ratio of 4.23 and a debt-to-equity ratio of 0.42.

Rapid Micro Biosystems (NASDAQ:RPID) last posted its earnings results on Friday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.26). The company had revenue of $7.84 million for the quarter, compared to analyst estimates of $7.60 million. Rapid Micro Biosystems had a negative return on equity of 73.90% and a negative net margin of 145.11%. On average, research analysts expect that Rapid Micro Biosystems, Inc. will post -1.1 earnings per share for the current year.

Institutional Investors Weigh In On Rapid Micro Biosystems

A number of large investors have recently made changes to their positions in the stock. Hudson Bay Capital Management LP acquired a new position in shares of Rapid Micro Biosystems in the 3rd quarter valued at $38,000. American Century Companies Inc. grew its stake in Rapid Micro Biosystems by 46.1% during the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock valued at $58,000 after purchasing an additional 5,341 shares during the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Rapid Micro Biosystems in the fourth quarter valued at about $72,000. XTX Topco Ltd purchased a new position in shares of Rapid Micro Biosystems in the second quarter worth about $144,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Rapid Micro Biosystems by 37.8% during the third quarter. Dimensional Fund Advisors LP now owns 55,642 shares of the company’s stock worth $186,000 after purchasing an additional 15,255 shares during the period. 52.60% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

RPID has been the topic of several analyst reports. Wall Street Zen lowered shares of Rapid Micro Biosystems from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.